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ABSTRACT
Background Several studies have reported a conflicting
association between cytomegalovirus (CMV) infection
and coronary artery disease (CAD) based on the levels of
total anti-CMV antibodies. However, none have
estimated the levels of specific neutralising antibodies
(NA) to CMV, which may be clinically more relevant.
Objective To determine whether CMVeNA titres show
a better association with CAD compared with total anti-
CMV antibody levels.
Design CMVeNA titres were measured by micro-
neutralisation assay and anti-CMV IgG antibodies using
ELISA in 391 consecutive CAD patients compared with
the same number of controls (N¼782), and 91 patients
reporting recurrent cardiac events during a 4-year follow-
up compared with those without a recurrent event
(N¼182). Levels of inflammatory markers, interleukin 6,
high-sensitivity C reactive protein, fibrinogen and
secretory phospholipase A2 (sPLA2), were measured by
ELISA. Analysis of variance and logistic regression were
used for statistical analyses.
Results High CMVeNA titres showed a positive
association with CAD occurrence (OR 2.24, 95% CI 1.31
to 3.85, p¼0.003) and recurrent cardiac events in CAD
patients (OR 4.65, 95% CI 1.21 to 17.86, p¼0.025)
compared with total CMV antibodies (OR 1.67, 95% CI
1.04 to 2.69, p¼0.034, and 2.70, 1.04 to 7.02,
p¼0.040, respectively). Patients with higher quartile of
CMVeNA titres and sPLA2 levels had an adjusted OR of
7.82 (95% CI 1.87 to 32.65, 0.005) for recurrent cardiac
events compared with those with the lowest quartiles
for both markers.
Conclusion These findings suggest that high CMVeNA
titres in combination with inflammatory markers improve
prediction of cardiac events in the Asian Indian
population.
INTRODUCTION
Human cytomegalovirus (CMV) can persist life-
long as a subclinical latent infection in an immu-
nocompetent host whereas it can cause signiﬁcant
morbidity and mortality in immunocompromised
patients. Viral genes modulate the host immune
system, mimic host chemokines and their recep-
tors,1 2 and play a role in the ensuing inﬂammatory
response.3
CMV can infect smooth muscle cells, enhance
cell proliferation, and induce early atherosclerotic
lesion formation and its subsequent progression.4 5
Viral glycoproteins, especially glycoprotein B and
glycoprotein H, mediate viral entry into the host
cell, and have been implicated as targets for virus-
neutralising antibodies (NA).6 7 NA titres differen-
tiate primary CMV infections from reactivated
ones, as these antibodies appear on average
13 weeks after the onset of primary infection, and
are consistently detected early during the reac-
tivated phase.8
Several epidemiological studies reported a posi-
tive association between CMV infection and coro-
nary artery disease (CAD).9 10 In animal models
also, CMV infection has been shown to exacerbate
atherosclerotic lesions.4 Regardless of enormous
epidemiological data, several questions still remain
unanswered. Is CMV infection a causative agent for
CAD or the inﬂammatory responses associated
with atherosclerosis lead to viral reactivation which
in turn activates inﬂammatory pathways related to
acute coronary syndrome? So far, an association
has been reported but no clear causative role has
been established. Despite these reports, several
studies have failed to show any association
between CMV infection and CAD.11 12 We there-
fore wanted to develop a more sensitive assay for
studying the association between CMV infection
and CAD. We hypothesised that estimating the
clinically relevant CMVeNA may be more perti-
nent to study their association with CAD than
total anti-CMV antibodies.
In this study, we investigated whether
CMVeNA titres, either alone or in association with
well-known inﬂammatory markers, would be
better predictors of risk for CAD occurrence and
recurrent cardiac events than total anti-CMV anti-
bodies in an Asian Indian population.
METHODS
Study population
The Indian Atherosclerosis Research Study (IARS)
is an ongoing nested case-control family based
study to investigate the molecular basis of athero-
thrombosis in Asian Indian Population.13 This
prospective study of individuals with and without
CAD at baseline was initiated in March 2004. In
the phase I of IARS, 2318 individuals were enrolled,
from 2004 to 2007, comprising of 774 CAD patients
and 1544 asymptomatic controls. Patients with
CAD had a positive angiogram, and were admitted
for coronary artery bypass graft surgery or percu-
taneous coronary intervention to participating
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hospitals in Bangalore and Mumbai, India. Family members over
18 years of age with normal ECG data who showed no CAD-
related symptoms and were apparently healthy were enrolled as
controls. The present analysis was carried out in an age- and
gender-matched population of 782 subjects, consisting of 391
consecutive CAD patients and 391 controls (Group I).
The IARS participants were followed-up from 2005 to 2010
(median follow-up time of 2.5 years). Acute coronary events
requiring hospitalisation and treatment, or fatal myocardial
infarction, were categorised as recurring cardiac events. Out of
774 CAD patients in the phase I of IARS, 91 patients (11.7%)
reported a recurrent cardiac event requiring hospitalisation and
treatment while 206 patients were lost to follow-up. To under-
stand the role of baseline CMVeNA titres in the recurrence of
cardiac events, an additional analysis was carried out in 182
CAD patients, consisting of 91 subjects who reported a recurrent
cardiac event matched to an additional 91 patients who did not
report a recurrent event during the same time period of follow-
up (Group 2) (ﬁgure 1). Blood samples (22 ml) were collected at
the time of recruitment, and serum and plasma separated and
stored at 808C in aliquots until use.
Individuals with a chronic illness, as deﬁned by WHO, or with
any concomitant infections were excluded from the study.
Information pertaining to demographics, lifestyle, anthropomet-
rics, and medical history of diabetes, hypertension, and medica-
tion use were recorded for each participant. Subjects with
a fasting blood sugar level >6.67 mMol/l were considered diabetic
and those with systolic/diastolic blood pressures >140/
90 mm Hg were considered hypertensive as per WHO guidelines.
The study was conducted following guidelines deﬁned by the
Indian Council of Medical Research and the Declaration of
Helsinki for undertaking human clinical research. An institu-
tional ethics committee approved the IARS study, and voluntary
signed informed consent was obtained from all participants.
NA assay
The CMV neutralisation assay was carried out as described
previously.14 Brieﬂy, serial twofold dilutions of the inactivated
(568C, 30 min) test serum were added to 96-well plates in
duplicates. Guinea pig complement was mixed with 13104
plaque-forming units/well of CMV (strain Towne (ATCC),
grown and titred in MRC-5 cells (European Collection of Cell
Cultures)) and added to serum-containing wells. The mixture of
test sera, complement and CMV in the plates was incubated for
60 min at 378C in a humidiﬁed 5% CO2 incubator. MRC-5 cells
were added at a density of 33104 cells/well following the
incubation period. Virus-infected cells in the absence of serum
were used as a control for complete cytopathic effects (virus
control). A pooled, normal human serum sample with a known
CMV neutralisation titre was used as a technical control in
every plate. Uninfected cells were plated as a cell-control in
every set of experiments. Plates were incubated for 5 days. The
ﬁnal neutralising titre of the sera was determined when the total
cytopathic effect developed in the virus control wells. The
reciprocal serum dilution demonstrating w99% protection
against the cytopathic effect of the virus was recorded as the NA
titre of the serum. The inter- and intra-assay coefﬁcients of
variation were 6.4% and 7.7%, respectively.
Assay for CMV antibodies by ELISA
Levels of immunoglobulin G (IgG) antibody to CMVantigens in
the serum were estimated using ELISA as per the manufacturer ’s
instructions (Adaltis, Rome, Italy). Optical density values were
converted into international units per millilitre of antibodies
based on standards provided in the kit.
Assay for inflammatory markers
Levels of inﬂammatory markers in the serum were estimated
using ELISA as per the manufacturer ’s instructions: interleukin
(IL)-6 (R&D systems, Minneapolis, Minnesota, USA), high-
sensitivity C reactive protein (hsCRP) (Immune Diagnostic,
USA), soluble intercellular cell adhesion molecule (sICAM)
(R&D systems) and secretory phospholipase A2 (sPLA2;
(Cayman Chemicals Company, Ann Arbor, Michigan, USA).
Fibrinogen was analysed on the ACL 300 automated coagulation
analyser (IL Systems, Milan, Italy) using clotting assays.
Figure 1 Study design showing the
details of patients and controls in
the two groups of analysis. Group 1:
The analysis was carried out in
a population of 782 subjects, consisting
of 391 consecutive coronary artery
disease (CAD) patients compared with
391 controls with matched age and
gender. Group 2: Analysis was carried
out in 182 CAD patients, consisting of
91 subjects who reported a recurrent
cardiac event matched to an additional
91 patients who did not report
a recurrent event during the same time
period of follow-up.
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Lipid assays
Total cholesterol, triglycerides and high-density lipoprotein
cholesterol (Bayer Diagnostics, Randox Laboratories, Dade-
Behring, UK) concentrations were determined on the Cobas Fara
II Clinical Chemistry auto analyser (F. Hoffman La Roche, Basal,
Switzerland), following the manufacturer ’s instructions. Serum
low-density lipoprotein cholesterol was calculated using Fried-
wald’s formula.15
Statistical analysis
The quantitative data were tested for normality using Kolmo-
goroveSmirnov test and were transformed using natural loga-
rithms wherever a deviation from normality was observed
(lipids levels, inﬂammatory markers and antibody titres). The
qualitative and categorical data were analysed using frequencies/
proportions. Baseline characteristics were compared between the
CAD patients and asymptomatic individuals (Group 1) and
between patients reporting recurrent events and those not
reporting an event (Group 2). To ensure the homogeneity in the
sample, the individuals in the two groups were matched for age
and gender. The epidemiological risk factors of hypertension,
diabetes, hyperlipidaemia body mass index, waist to hip ratio,
current smoking and statin use were used as covariates in the
analysis of variance.
In the baseline information, the categorical variables were
tested using c2 tests and univariate analysis of variance and
Student t test were used for testing the mean differences in
various groups. Numerical results are expressed as mean (SEM).
Multivariate analysis of variance was used to compare the mean
levels of anti-CMV antibodies and CMVeNA titres and
inﬂammatory markers between the different groups. To estimate
the risk association of higher levels of anti-CMV antibodies and
CMVeNA titres for CAD and its recurrence, the values are
categorised into four quartiles. The risks of higher quartiles were
assessed using logistic regression models using the ﬁrst quartile
as reference. In the logistic regression models with multiple
biomarkers, risk associations were identiﬁed taking the ﬁrst
quartiles of both as the reference. ORs and their 95% CIs were
obtained as estimates of associated risk for CAD. The receiver
operating characteristic (area under the curve; AUC) analysis
and C-Statistics are obtained to assess the contributing markers
and as a criterion for model selection when multiple markers are
used in the logistic regression. Statistical analyses were
performed using SPSS V.17.0 for Windows and a p value <0.05
was considered statistically signiﬁcant.
RESULTS
Baseline characteristics
Baseline characteristics of the study participants are shown in
table 1. Mean age of the study population was 55.060.7 years.
The prevalence of hypertension, diabetes and smoking was
higher in patients compared with controls while lipid levels were
lower in patients, corresponding to a higher statin use.
During a follow-up period of 5 years (median 2.5 years), 91
patients reported an acute coronary event, 19 of which were
fatal. Prevalence of hypertension and smoking were higher in
CAD patients who reported a recurrent cardiac event compared
with patients without a recurrent event. Patients with recurring
cardiac events also had higher mean levels of hsCRP, sPLA2 and
ﬁbrinogen (table 1).
Mean levels of NA and anti-CMV IgG antibodies in study
population
The mean baseline NA titres were signiﬁcantly higher in CAD
patients compared with asymptomatic individuals for unad-
justed model (p<0.001), and after adjustment for established
risk factors (body mass index, waist to hip ratio, hypertension,
diabetes, hyperlipidaemia, current smoking) and statin use.
Table 1 Baseline characteristics
Variable
Total population (n[782) Group 1 Follow-up patients (n[182) Group 2
Asymptomatic
individuals (n[391)
CAD patients
(n[391)
Without recurrent
event (n[91)
With recurrent
event (n[91)
Demographic
Age, years 53.0660.50 53.5760.50 57.1660.98 57.0860.98
Gender (male/female) 67.6%/32.4% 66.5%/33.5% 80.2%/19.8% 80.2%/19.8%
Presenting characteristic
BMI, kg/m2 25.9360.21 26.1060.21 25.6760.41 26.0560.42
Waist to hip ratio 0.9360.004 0.9360.004 0.9460.01 0.9460.01
Systolic blood pressure, mm Hg 127.9160.90 127.9560.89 132.0661.94 127.0761.94
Diastolic blood pressure, mm Hg 83.6560.48* 81.7260.48* 83.5260.99 81.3060.99
Hypertension 30.3%* 51.0%* 47.3% 65.9%*
Diabetes 25.0%* 46.8%* 46.2% 57.1%
Current smoking 7.2%* 10.9%* 4.4% 6.6%*
Statin use 5.3%* 69.5%* 62.2% 68.9%
Serum cholesterol, mMol/l
Total cholesterol* 4.7260.51* 3.9460.05 3.8860.11 4.1860.11
Triglycerides* 1.6260.04 1.7160.03 1.6660.07 1.5860.07
High-density lipoprotein* 1.0460.01* 0.9660.01 0.9360.02 0.9960.02*
Low-density lipoprotein* 2.9460.04* 2.2060.04 2.1960.09 2.4660.10
Inflammatory markers
hsCRP,* ug/ml 3.5360.27 3.7860.26 3.4760.55 3.6960.66
sPLA2,* pg/ml 3699.496179.73 4143.136178.58 3609.106387.10 3821.576394.56
IL-6,* pg/ml 4.1660.61* 6.3460.61* 5.0160.66 4.9760.68
Fibrinogen,* mg/dl 3.8560.05* 4.1260.05* 4.1560.10 4.0560.10
Values are per cent or mean6SE of mean (SEM).
*p<0.05.
BMI, body mass index; CAD, coronary artery disease; hsCRP, high-sensitivity C reactive protein; IL-6, interleukin 6; sPLA2, secretory
phospholipase A2.
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Although concentrations of anti-CMV IgG antibodies were
higher in CAD patients (p¼0.022) compared with controls, the
difference became non-signiﬁcant following adjustment for risk
factors in patients with recurrent events versus without recur-
rent events (p<0.001) (table 2).
Mean baseline titres of CMVeNAwere also signiﬁcantly higher
in patients reporting recurrent events (p<0.001) compared with
those without one, but the anti-CMV IgG antibody levels were
comparable between these two groups (table 2).
Higher odds for CAD occurrence associated with CMVeNA
versus anti-CMV IgG antibodies
Logistic regression analysis showed a strong association between
CMVeNA titres and CAD occurrence when the fourth and ﬁrst
quartiles of CMVeNA levels were compared (OR 1.89, 95% CI
1.18 to 2.99, p¼0.007) (table 3). The ORs increased and
remained signiﬁcant (OR 2.25, 95% CI 1.31 to 3.85, p¼0.003)
after adjusting for risk factors.
The ORs for the association between anti-CMV IgG and CAD
were lower compared with CMVeNA for the unadjusted model
(OR 1.57, 95% CI 1.05 to 2.35, p¼0.028) as well as the adjusted
model (OR 1.67, 95% CI 1.04 to 2.69, p¼0.034) (table 3).
Higher risk of recurrent cardiac events is associated with
increased CMVeNA titres
The association between CMVeNA titres and recurrent CAD
over the 4-year follow-up was assessed using age- and gender-
matched patients who did not report a recurrent event. The risk
of a recurrent event increased in the higher quartiles of
CMVeNA titre. The OR was 1.32 (0.35 to 5.02), p¼0.68 for the
second quartile, 2.98 (0.74 to 11.96), p¼0.743 for the third
quartile and was the highest at 4.65 (1.21 to 17.86), p¼0.025
when the CMVeNA titres were in the fourth quartile (table 3).
CMV IgG antibodies did not show a signiﬁcant association with
recurrent cardiac events (OR of 2.35 (0.95 to 5.83), p¼0.064 for
the highest quartile).
Risk association of CMVeNA titres combined with inflammatory
markers
To further examine the discriminatory power of the CMVeNA
titres in the presence of other inﬂammatory markers, risk asso-
ciation and c-statistics analysis were carried out. The ORs for
CAD occurrence ranged between 2.24 and 2.68, with AUC
values ranging between 0.783 to 0.785, when NA titres and
biomarkers in the fourth quartile were compared with the ﬁrst
quartiles. Only marginal increases in the OR were observed in
the presence of hsCRP (2.68 (1.52 to 4.73), p¼0.001) and
ﬁbrinogen (2.32 (1.35 to 3.99), p¼0.002) compared with that of
CMVeNA alone (2.25 (1.31 to 3.85), p¼0.003) (table 4).
The ORs for recurrent cardiac events increased from 4.65 (1.21
to 17.86), p¼0.025 for CMVeNA alone to 7.82 (1.87 to 32.65),
p¼0.005 in the presence of sPLA2 and CMVeNA titres (table 4).
Similar increases were observed in the presence of IL-6 (5.56
(1.50 to 20.65), p¼0.010) and ﬁbrinogen (5.05 (1.37 to 18.55),
p¼0.015). The addition of inﬂammatory markers did not
Table 2 Mean levels of CMVeNA titres and CMV antibody levels for the study population
Model Control (n[391) CAD patients (n[391) p Value
A. Group 1: CAD patients versus controls
CMVeNA titres
Unadjusted 4.71660.051 4.96660.050 <0.001
Adjusted for risk factors* 4.75460.064 4.94360.106 0.018
Anti-CMV antibodies, IU/ml
Unadjusted 2.11460.058 2.30260.057 0.022
Adjusted* 2.10460.074 2.37360.121 0.13
Model
CAD patients
p ValueWithout recurrent event (n[91) With recurrent event (n[91)
B. Group 2: CAD patients with versus without recurrent events during follow-up
CMVeNA titres
Unadjusted 4.65260.097 5.16060.099 <0.001
Adjusted for risk factors* 4.74560.126 5.20360.132 0.003
Anti-CMV antibodies, IU/ml
Unadjusted 2.16860.117 2.27060.117 0.54
Adjusted* 2.39560.150 2.37760.157 0.54
Values are log-transformed mean6SEM.
*Body mass index, waist to hip ratio, hypertension, diabetes, hyperlipidaemia, current smoking and statin use.
CAD, coronary artery disease; CMV, cytomegalovirus; NA, neutralising antibodies.
Table 3 Comparison of risk association of CMVeNA and anti-CMV IgG
antibodies with CAD
Unadjusted model Adjusted for risk factors*
OR (95% CI), p value
A. OR for CAD
CMVeNA
Q2 1.27 (0.76 to 2.12), 0.350 1.43 (0.79 to 2.61), 0.240
Q3 1.06 (0.66 to 1.70), 0.800 1.16 (0.67 to 2.01), 0.591
Q4 1.89 (1.18 to 2.99), 0.007 2.24 (1.31 to 3.85), 0.003
CMV IgG antibodies
Q2 1.38 (0.93 to 2.08), 0.110 1.14 (0.71 to 1.83), 0.571
Q3 1.56 (1.05 to 2.34), 0.029 1.60 (1.03 to 2.55), 0.048
Q4 1.57 (1.05 to 2.35), 0.028 1.67 (1.04 to 2.69), 0.034
B. OR for recurrent cardiac events
CMVeNA
Q2 1.56 (0.42 to 5.80), 0.500 1.32 (0.35 to 5.02), 0.680
Q3 3.56 (1.01 to 12.64), 0.050 2.98 (0.74 to 11.96), 0.740
Q4 5.68 (1.66 to 19.42), 0.006 4.65 (1.21 to 17.86), 0.025
CMV IgG antibodies
Q2 1.00 (0.42 to 2.36), 0.999 0.95 (0.37 to 2.42), 0.900
Q3 0.89 (0.38 to 2.07), 0.801 0.90 (0.36 to 2.22), 0.820
Q4 2.26 (0.94 to 5.41), 0.067 2.35 (0.95 to 5.83), 0.064
ORs were calculated by logistic regression analysis using the first quartile as reference.
*Age, gender, body mass index, waist to hip ratio, hypertension, diabetes, current smoking,
hyperlipidaemia and statin use.
CAD, coronary artery disease; CMV, cytomegalovirus; IgG, immunoglobulin G;
NA, neutralising antibodies; Q, quartile of CMVeNA titre.
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inﬂuence the discriminatory power of CMVeNA, since the AUC
values only increased from 0.702 to a maximum of 0.729 (in the
presence of IL-6) (table 4). The addition of inﬂammatory
markers to total anti-CMV antibodies did not result in a signiﬁ-
cant OR for CAD or recurrent cardiac events (table 4).
DISCUSSION
In the present study, we report a signiﬁcant association between
CMVeNA titres and CAD, and more importantly, recurrent
cardiac events, in an Indian population. We also demonstrate an
increased risk of recurrent cardiac events in CAD patients in the
presence of sPLA2 or IL-6 along with CMVeNA in the same
model. The increase in ORs in the presence of inﬂammatory
markers was highly signiﬁcant with CMVeNA titres but not
with anti-CMV IgG ELISA antibodies. These results establish
the importance of estimating clinically relevant antibodies and
are in line with our hypothesis that estimating speciﬁc anti-
bodies gives a better understanding of the association between
infection and CAD.
CAD is currently the most prevalent non-communicable
disease in India and is a leading cause of morbidity and
mortality.16 17 Indians are also reported to have a higher inci-
dence and prevalence of CAD at a younger age compared with
other populations, leading to a greater social and economic
impact.17 18 Greater concern in recent years has been a steady
increase in CAD related deaths in the rural Indian population
who show a higher prevalence of cardiovascular risk factors
including diabetes, hypertension and obesity.16 Preventive
medical care is less accessible for the rural Indian population and
consequently these patients have a higher risk of acute coronary
syndromes. Infection and related burden of pathogen are also
reported to be higher in the Indian population.19 We have
previously noted that pathogen burden, especially CMV infec-
tion, plays an important role in CAD occurrence in the Asian
Indian population (unpublished observation).
Viral glycoproteins mediate the entry of virus into the suscep-
tible cells while antibody response against glycoproteins is an
important defence mechanism, as these antibodies are capable of
neutralising infectious viruses.6 7 High titres of NA have been
associated with improved survival after infection while a decline
in their titre was associated with viral reactivation in immuno-
suppressed patients.20 Since CMV can infect cardiac smooth
muscle cells, reactivation of the virus may accelerate atherogenic
process by activating the immune inﬂammatory responses.
Although ELISA can measure antibodies for speciﬁc antigens from
CMV, neutralisation of viral entry into cells can establish biolog-
ical activity of CMV antigen speciﬁc antibodies. Therefore, esti-
mation of NA against CMV should correlate better with CAD
and recurrent cardiac events in patients.
In the present study, we found signiﬁcantly higher mean levels
of CMVeNA titres, but not total antibodies to CMV, in CAD
patients compared with asymptomatic controls. The basal mean
CMVeNA titres were also signiﬁcantly higher in patients
reporting a recurrent cardiac event compared with those without
any recurrent events, suggesting that CMVeNA titres are more
relevant for association studies. In substantiation, we observed 1.5-
fold higher ORs for CAD occurrence and recurrent cardiac events
with CMVeNA titres compared with total CMV antibodies.
Inﬂammation plays a major role in the manifestation of CAD.
Systemic infections can promote inﬂammatory reactions in the
vessel wall leading to progression of atherosclerosis.21 Antigens
from CMV and the viral DNA have been identiﬁed in the
atherosclerotic lesions of human and mice, suggesting an
inﬂammatory role of CMV in the progression of the disease.4
Presence of the virus in the vessel wall induces smooth muscle-
cell proliferation and migration, increased uptake of oxidised
low-density lipoproteins, expression of inﬂammatory cytokines
and an increased procoagulant activity leading to disease
progression.21 CMV can also cause molecular mimicry wherein
an immune response to viral antigens can cross react with self-
peptides expressed on uninfected host cells.21 22 Thus, multiple
mechanisms are likely to contribute to the risk association
between CMV infection and CAD.
CMV infection is known to increase plasma interferon-g
(IFN-g) and tumour necrosis factor a (TNF-a) levels in rodents
and induce IL-6 release, triggering the release of acute-phase
proteins such as C reactive protein and exacerbating local
inﬂammation.23 These inﬂammatory cytokines can stimulate
sPLA2 release from vascular smooth muscle cells, the proposed
link between inﬂammation and lipid accumulation in athero-
sclerosis.24 Serum levels of sPLA2 show an association with CAD
risk and recurrent CAD events.25 In humans, sPLA2 has been
detected in both early and advanced atherosclerotic lesions.
Interestingly, the presence of CMV DNA in the lesion is asso-
ciated with sPLA2 expression and inﬂammation.26 The protein
has also been suggested to have a role in inﬂammatory damage
to the heart ensuing in infarcted myocardium.27 We chose IL-6,
hsCRP and sPLA2 as markers of a subsequent inﬂammatory
Table 4 Association of CMV-NA and anti-CMV IgG antibodies with CAD and recurrent cardiac events in the presence of inflammatory markers
Model
CMVeNA CMV IgG
OR (95% CI), p Value AUC, p Value OR (95% CI), p Value AUC, p Value
A. Association of CMVeNA and anti-CMV IgG antibodies with CAD in the presence of other inflammatory markers
Antibody titres alone 2.24 (1.31 to 3.85), 0.003 0.783, <0.001 1.67 (1.04 to 2.69), 0.034 0.777, <0.001
+ IL-6 2.15 (1.23 to 3.74), 0.007 0.784, <0.001 1.47 (0.91 to 2.38), 0.114 0.774, <0.001
+ sPLA2 2.17 (1.27 to 3.70), 0.017 0.782, <0.001 1.57 (0.98 to 2.50), 0.060 0.775, <0.001
+ hsCRP 2.68 (1.52 to 4.73), 0.001 0.774, <0.001 1.48 (0.91 to 2.40), 0.116 0.765, <0.001
+ Fibrinogen 2.32 (1.35 to 3.99), 0.002 0.785, <0.001 1.47 (0.92 to 2.34), 0.105 0.778, <0.001
B. Association of CMVeNA and anti-CMV IgG antibodies with risk of recurrent cardiac events in the presence of other inflammatory markers
Antibody titres alone 4.65 (1.21 to 17.86), 0.025 0.702, <0.001 2.35 (0.95 to 5.83), 0.064 0.674, <0.001
+ IL-6 5.56 (1.50 to 20.65), 0.010 0.729, <0.001 2.51 (0.98 to 6.38), 0.053 0.697, <0.001
+ sPLA2 7.82 (1.87 to 32.65), 0.005 0.712, <0.001 1.62 (0.57 to 4.58), 0.363 0.701, <0.001
+ hsCRP 2.31 (1.39 to 3.85), 0.001 0.715, <0.001 1.77 (0.57 to 4.58), 0.779 0.684, <0.001
+ Fibrinogen 5.05 (1.37 to 18.55), 0.015 0.703, <0.001 2.81 (1.07 to 7.36), 0.036 0.691, <0.001
ORs were computed for antibody levels in the fourth quartile in the presence of quartiles of inflammatory markers using the first quartile as reference.
The models were adjusted for age, gender, body mass index, waist to hip ratio, hypertension, diabetes, current smoking, hyperlipidaemia and statin use.
AUC, area under the curve; CAD, coronary artery disease; CMV, cytomegalovirus; hsCRP, high-sensitivity C reactive protein; IgG, immunoglobulin G; IL-6, interleukin-6; NA, neutralising
antibodies; sPLA2, secretory phospholipase A2.
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response after CMV infection, as these are directly related to
virus-induced pathogenesis. Although addition of inﬂammatory
markers to CMVeNA titres resulted in only minor changes in
the OR for CAD occurrence, CAD patients in the highest
quartile of CMVeNA and sPLA2 had a 4.7-times increase in the
OR for recurrent cardiac events. Addition of inﬂammatory
markers to total CMVantibodies had minor or no change in the
OR for CAD occurrence as well as recurrent events. These
observations suggest that CMV infection as measured by NA
levels in combination with inﬂammatory markers such as sPLA2
may improve risk prediction in the Asian Indian population.
Earlier studies have suggested that individuals with a subclin-
ical inﬂammatory proﬁle, as measured by CRP levels, have
a higher susceptibility to CMV-induced atherogenic effects.28 In
our study, we did not observe an association between CRP levels
and CMV infection, probably because of high statin use in the
patient population, which has been reported to downregulate C
reactive protein levels.29
The strengths of our study include the cohort of relatively
young Asian Indian CAD patients, and age- and gender-matched
asymptomatic controls, the assessment of covariates, and
adjustment for confounding factors. The limitations comprise
short follow-up and the collection of samples after the CAD
event, which limit causal interpretation of the relationship
between CMVeNA titres and CAD risk. During this time, we
had only 21 asymptomatic individuals reporting a new event.
Based on a follow-up of 8e10 years to predict cardiovascular
risk, as described in major studies,30 our future studies will
include a larger cohort and longer follow-up to strengthen our
hypothesis. Micro-neutralisation assay to estimate CMVeNA
titres is time- and labour-intensive compared with ELISA. We are
also developing methods to reduce the assay time without
compromising its sensitivity.
In summary, our results reinforce the importance of CMV
infection and the signiﬁcance of estimating clinically relevant
antibodies to pathogens in cardiovascular risk assessment.
Further validation in different ethnic populations is required to
conﬁrm our hypothesis.
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